This is probably the biggest concern that every community and cancer practice should be looking at, explained Ben Jones, vice president, Government Relations & Public Policy, McKesson Specialty Health.
This is probably the biggest concern that every community and cancer practice should be looking at, explained Ben Jones, vice president, Government Relations & Public Policy, McKesson Specialty Health.
Transcript
CMS has proposed allowing step therapy in Medicare Advantage plans for Part B drugs. How do you think this will impact cancer patients?
This is probably the biggest concern that every community and cancer practice should be looking at. The president has come out with a number of proposals included in the drug pricing blueprint that have a specific impact on Part B drugs. The secretary made it clear when the drug pricing proposal was released that his desire was to, as much as his ability allows, move Part B drugs into Part D. In absent the ability to kind of make an easy shift into Part D, what he wants to do is mimic some of the characteristics that Part D has in the Part B space. That’s why you’re seeing such quick action on step therapy, on a relaxing of the protected classes, and on a number of utilization management tools that are likely to come down the pipe.
I do think that this is something that has the biggest potential to threaten access to care for cancer patients across the country. These are just 2 examples. Step therapy and protected classes have already been finalized. The changes to both of those proposals have been finalized in Medicare Advantage, but we’ve also got another proposal with the International Pricing Index that again has the potential to insert a new third-party vendor into the drug supply chain, impacting access to patient timely care and potentially a new round of utilization management tools.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More